Lirilumab

Drug Profile

Lirilumab

Alternative Names: Anti-KIR (1-7F9); Anti-KIR monoclonal antibody - Innate Pharma; BMS-986015; IPH-21; IPH-2101; IPH-2102; LIRI; NN 1975

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Bristol-Myers Squibb; Innate Pharma; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies; Multiple myeloma
  • Preclinical Lymphoma
  • Discontinued Acute myeloid leukaemia; Hepatitis C

Most Recent Events

  • 13 Mar 2017 Bristol-Myers Squibb amends the clinical trial protocol for phase I/II trial in Solid tumours (Combination Therapy)
  • 07 Mar 2017 Updated efficacy data from a phase I/II trial in Solid tumours released by innate Pharma
  • 07 Mar 2017 Discontinued - Phase-II for Acute myeloid leukaemia (In the elderly) in France (IV) due to negative top-line results from the EffiKiR trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top